DJIA 17,164.95 -251.90 -1.45%
NASDAQ 4,635.24 -48.17 -1.03%
S&P 500 1,994.99 -26.26 -1.30%
market minute promo

PTC Therapeutics, Inc. (NASDAQ: PTCT)

54.91 -0.52 (-0.94%)

Quote as of


company name or ticker

Recent Quotes

PTCT $54.91 -0.94%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $55.14
Previous Close $55.43
Daily Range $54.29 - $56.58
52-Week Range $14.51 - $61.17
Market Cap $1.8B
P/E Ratio -26.15
Dividend (Yield) $0.00 (0.0%)
Volume 248,834
Average Daily Volume 384,505
Current FY EPS -$3.22

Sector

Industry

PTC Therapeutics, Inc. (PTCT) Description

PTC Therapeutics, Inc. Website: http://www.ptcbio.com/

News & Commentary

The Market's Top 10 Stocks of 2014

Taking a look back at the past year reveals some investing lessons you can use in the future.

Convert Catalysts Into Profits: Sagient Research's Edward Stopke

Deutsche Bank's Top Biotech Picks For 2015

New Lifetime High Reached By PTC Therapeutics (PTCT)

Jim Cramer's Top Stock Picks: GD PTCT RLYP HON PEP

Sarepta Is Suffering From Overreaction

PTC Therapeutics Starts Rolling NDA Filing for Translarna - Analyst Blog

PTC Therapeutics Starts Rolling NDA Filing for Translarna - Analyst Blog

PTC Therapeutics Begins Rolling NDA Submission to the FDA for Translarna to Treat Duchenne Muscular

PTC Therapeutics Begins Rolling NDA Submission to the FDA for Translarna to Treat Duchenne Muscular Dystrophy

3 Drugmakers Facing a Pivotal 2015

Isis Pharmaceuticals, PTC Therapeutics, and GW Pharmaceuticals all expect 2015 to be a pivotal year in their drive toward becoming commercially viable entities. Should investors jump in before the catalysts spark?

PTC Therapeutics (PTCT) Downgraded From Hold to Sell

See More PTCT News...